COVID-19
Conditions
Interventions
Control group:Xuantou Jiedu Granule Placebo 1 bag *4 times/day
Experimental group:Xuantou Jiedu Granule 1 bag *4 times/day
Sponsors
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Confirmed cases of mild COVID-19 infection; 2.Age = 18 years, < 65 years; 3.Course of disease =48 hours and body temperature =37.5?; 4.Signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Pregnant women or puerperal women; 2.Patients with mental illness or others who are unable or unwilling to cooperate; 3.Participants within the last 1 month or currently participating in similar clinical trials; 4.Patients with chronic lung disease, malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease and endocrine system disease, as determined by researchers, Immune dysfunction (such as AIDS patients, long-term use of corticosteroids or other immunosuppressive drugs resulting in immune dysfunction), obesity (body mass index =30), heavy smokers, may affect the outcome of patients participating in trials or studies; 5.Patients have received or are receiving anti-COVID-19 drugs such as paxlovid and azifudine tablets; 6.Allergy, such as a history of allergy to two or more drugs or foods, or known allergy to the ingredients of the drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete antipyretic time; | — |
Secondary
| Measure | Time frame |
|---|---|
| COVID-19 symptom score;Incidence and severity ratio of COVID-19 pneumonia;Time and rate of first negative antigen conversion;Application of antipyretic drugs;Lymphocyte count and C-reactive protein; | — |
Countries
China
Contacts
Public ContactRui Cao
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
Outcome results
None listed